Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Researchers at Dana-Farber Cancer Institute have found that modest
racial disparities remain in breast cancer care even when socioeconomic
and insurance differences are accounted for.
The findings, reported online by the journal Cancer, are the
first to examine these factors in a large-scale, national study of a
diverse patient population, said the scientists, led by Rachel Freedman, MD, MPH, of Dana-Farber's Breast Oncology Center. Freedman said that further study is needed to identify other explanations for the treatment gap.
"We found that there are modest racial disparities in receiving
recommended treatments for early breast cancer," said Freedman. "These
disparities didn't go away when we accounted for differences in health
insurance coverage or the socioeconomic status of areas where the women
"This is a reminder that, even with the current movements to expand
health insurance coverage, some racial disparities in care may remain."
Using a national, hospital-based database of 662,117 white, black and
Hispanic women diagnosed with early stage invasive breast cancer. The
study focused on comparisons of white and black women.
In general, the black women were younger, had more advanced cancer at
diagnosis, and were more often uninsured or had Medicaid coverage. They
also tended to live in areas with lower high-school graduation rates
and lower median incomes.
The scientists computed the percentage of women who had received care
according to a set of professional guidelines. These guidelines
contained four recommended elements in treating women with early-stage
As expected from previous studies, the analysis revealed significant
racial differences – around 10 percent – in receipt of recommended
treatments except for hormone receptor status testing, which was almost
always performed and was equal across the groups.
In a subsequent analysis, the researchers asked whether blacks might
be less likely to receive optimal care because of inferior insurance
coverage or having lower incomes and education levels (socioeconomic
status, or SES).
For both blacks and whites, SES factors were not associated with
differences in any of the treatment categories. The type of insurance
coverage did affect the odds of receiving recommended treatments; lower
odds were associated with lack of insurance, Medicaid coverage, and
younger Medicare patients compared with those privately insured.
"These differences are modest, but they are important given the large
number of women who are diagnosed with early stage breast cancer," said
The findings leave the researchers wondering what else might be responsible for the persistent disparities.
Previous studies in the field have pointed to a number of potential
contributing factors, Freedman said, including blacks' personal
preferences and mistrust of the medical system; doctors' biases in
recommending treatments; access to care even when insurance coverage is
the same; and characteristics of the facilities in which whites and
blacks tend to receive their care.
Whatever the causes, said Freeman, greater efforts are needed to
ensure that all women receive the most effective breast cancer care
regardless of their race or ethnicity. Dana-Farber investigators are
participating in a follow-up study that will explore some of these
issues, she said.
Other authors of the paper include senior author Nancy Keating of
Brigham and Women's Hospital and Harvard Medical School; Elizabeth Ward
of the American Cancer Society, and Eric Winer of Dana-Farber.
The research was supported by a grant from Susan G. Komen for the Cure.